Shadia I Jalal MD

Oncology•Indianapolis, IN

Gastrointestinal Cancer, Thoracic Cancer

Professor of Medicine, Lawrence H. Einhorn Chair in Oncology, Indiana University School of Medicine

Join to View Full Profile

535 Barnhill DrIndianapolis, IN 46202
Phone+1 317-274-3658

Summary

Shadia Jalal, MD is an oncologist based in Indianapolis, IN, with subspecialties in esophagogastric cancers and thoracic cancer. Her education mainly took place at the Indiana University School of Medicine, where she completed a fellowship in Hematology and Medical Oncology and a residency in Internal Medicine. She earned her medical degree from the University of Jordan Faculty of Medicine. Dr. Jalal has significant experience in treating lung and esophagogastric cancers and has published several research papers on various oncology-related topics, and has been cited multiple times in other publications. Additionally, she has been involved in diverse clinical trials, often assuming the role of Principal Investigator. She is a Professor of Medicine at IUSM and the Lawrence H. Einhorn Chair in Oncology. She is a funded physician scientist.

Education & Training

Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
Indiana University School of MedicineResidency, Internal Medicine, 2003 - 2006
University of Jordan Faculty of MedicineClass of 2002

Certifications & Licensure

IN State Medical License 2009 - 2025
American Board of Internal Medicine Medical Oncology

Clinical Trials

Study of RAD001 + AMG479 for Patients With Advanced Solid Tumors Start of enrollment: 2010 May 14
Completed
Phase 1
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer Start of enrollment: 2010 Sep 21
ACTIVE_NOT_RECRUITING
PHASE2
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer Start of enrollment: 2013 Feb 01
Terminated
Phase 2, Phase 3
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
COMPLETED
PHASE3
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Circulating Tumor Cells (CTC) in Lung Cancer Start of enrollment: 2017 Oct 19
RECRUITING
A Study of Durvalumab (MEDI4736) in Esophageal Cancer Start of enrollment: 2016 Apr 27
Completed
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
ACTIVE_NOT_RECRUITING
PHASE3
Fasting-mimicking Diet With Chemo-immunotherapy in Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2018 Nov 02
Completed
Not Applicable
A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma Start of enrollment: 2019 Jul 09
Terminated
Phase 2
Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer Start of enrollment: 2019 Jun 06
Completed
Phase 2
Beyond the Lung Cancer Diagnosis: Leveraging the Oncology Clinic Setting for Actively Smoking Family Members Start of enrollment: 2021 Sep 13
Terminated
ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) Start of enrollment: 2021 Sep 15
TERMINATED
PHASE2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage...
Greg Durm, Hirva Mamdani, Sandra Althouse, Susan Perkins, Salma K Jabbour
Journal for Immunotherapy of Cancer. 2025-07-15
Gastric Cancer, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Jaffer A Ajani, Thomas A D'Amico, David J Bentrem, Carlos U Corvera, Prajnan Das
Journal of the National Comprehensive Cancer Network. 2025-05-01
Correlates of Perceived Illness Severity and Terminality in Advanced Lung and Prostate Cancer.
Michaela Di Palmo, Ekin Secinti, Ellen Krueger, Nasser H Hanna, Nabil Adra
Journal of Pain and Symptom Management. 2025-04-01

Journal Articles

Abemaciclib in Combination with Single-Agent Options in Patients with Stage IV Non-Small Cell Lung Cancer: A Phase 1b Study
Karen Kelly, Montaser Shaheen, Shadia Jalal, Daruka Mahadevan, Clinical Cancer Research

Press Mentions

'No' to Anti-VEGF-Chemo Combo in NSCLC Sans Driver AlterationsFebruary 10th, 2023
Lung Cancer Experts Available from Indiana UniversityNovember 1st, 2017